Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency

Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency

Bibliographic Details
Main Authors:	Ducruet Thierry, Levasseur Marie-Claude, Des Roches Anne, Dicaire Renée, Haddad Elie
Format:	Article
Language:	English
Published:	BMC 2011-11-01
Series:	Allergy, Asthma & Clinical Immunology

Similar Items

Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
by: Scheuerlein, P, et al.
Published: (2018)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
by: Suzanne Skoda-Smith, et al.
Published: (2009-12-01)

Intravenous immunoglobulin therapy.
by: Chapel, H
Published: (1996)

Use of Intravenous Immunoglobulin Therapy in a paediatric rheumatology service
by: Saladi SM, et al.
Published: (2008-09-01)

Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy
by: Mona Al-Ahmad, et al.
Published: (2017-01-01)

Experience with subcutaneous immunoglobulin therapy in two pediatric cases of immune thrombocytopenia purpura
by: Chapdelaine H, et al.
Published: (2012-11-01)

The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy
by: Bjorkander, J, et al.
Published: (2000)

Does intravenous immunoglobulin therapy prolong immunodeficiency in transient hypogammaglobulinemia of infancy?
by: Lale Memmedova, et al.
Published: (2013-09-01)

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
by: Kobrynski L
Published: (2012-08-01)

Neutropaenia following intravenous immunoglobulin therapy in paediatric patients with immune thrombocytopaenia
by: Martyna Szuster, et al.
Published: (2024-06-01)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
by: Jolles S
Published: (2013-09-01)

Home intravenous immunoglobulin therapy.
by: Chapel, H, et al.
Published: (1988)

Intravenous Immunoglobulin Therapy in Myocarditis
by: Amir Hossein Mansourabadi, et al.
Published: (2020-08-01)

Immunoglobulin replacement therapy for primary immunodeficiencies.
by: Peter, J, et al.
Published: (2014)

Use of Intravenous Immunoglobulins in Intensive Therapy
by: E. A. Latysheva, et al.
Published: (2012-06-01)

Subcutaneous immunoglobulin replacement therapy: the European experience.
by: Chapel, H, et al.
Published: (2013)

Advantage of the subcutaneous immunoglobulin replacement therapy in primary immunodeficient patients with or without secondary protein loss
by: Pınar Gür-Çetinkaya, et al.
Published: (2018-06-01)

The effect of subcutaneous immunoglobulin replacement therapy on serum IgG levels in patients with primary immunodeficiency
by: Selime Özen Bölük, et al.
Published: (2023-06-01)

Intravenous Immunoglobulin Therapy in COVID-19 Disease
by: Öner Özdemir, et al.
Published: (2021-06-01)

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
by: Paul K. Keith, et al.
Published: (2022-08-01)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
by: M. Dolenc-Voljč, et al.
Published: (2013-11-01)

Idiotype-specific intravenous immunoglobulin for therapy of immunoglobulin kappa free light chain deficiency
by: Adina Elena Stanciu, et al.
Published: (2019-05-01)

Sentiment analysis of subcutaneous and intravenous immunoglobulin therapy: public healthcare perception through social media discourse
by: Alejandro Tarango-García, et al.
Published: (2024-10-01)

Adverse Reaction Following Intravenous Immunoglobulin in Primary Immunodeficiency Patients
by: J. Ghaffari, M.D.+, et al.
Published: (2007-01-01)

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
by: Martin Adriana, et al.
Published: (2012-11-01)

Subcutaneous immunoglobulin replacement therapy in patients with immunodeficiencies – impact of drug packaging and administration method on patient reported outcomes
by: R. Mallick, et al.
Published: (2024-02-01)

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
by: Paul K. Keith, et al.
Published: (2023-06-01)

Effectiveness of Intravenous Immunoglobulin Therapy for Pediatric Viral Encephalitis
by: Ji Eun Byun, et al.
Published: (2020-10-01)

Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease
by: Hyo Min Park, et al.
Published: (2013-02-01)

Neonatal sepsis and transient immunodeficiency: Potential for novel immunoglobulin therapies?
by: Coco R. Beudeker, et al.
Published: (2022-10-01)

A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases
by: Kristin Epland, et al.
Published: (2022-09-01)

Timing of infections in patients with primary immunodeficiencies treated with intravenous immunoglobulin (IVIg)
by: Parwinder K. Gill, et al.
Published: (2018-08-01)

Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
by: Martin Adriana, et al.
Published: (2012-11-01)

Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens
by: Chouksey Akhilesh, et al.
Published: (2005-09-01)

OUTBREAK OF ACUTE HEPATITIS-C FOLLOWING INTRAVENOUS IMMUNOGLOBULIN THERAPY
by: Healey, C, et al.
Published: (1994)

Intravenous immunoglobulin therapy in erythromelalgia management: a case report
by: Renato Ádler Pomilio de Sousa, et al.
Published: (2025-03-01)

ADVERSE EFFECTS OF INTRAVENOUS IMMUNOGLOBULIN THERAPY IN PATIENTS WITH ANTIBODY DEFICIENCY
by: A. Aghamohammadi, et al.
Published: (2003-09-01)

INTRAVENOUS IMMUNOGLOBULIN IN PEDIATRICS
by: A.Yu. Shcherbina, et al.
Published: (2010-07-01)

INTRAVENOUS IMMUNOGLOBULIN IN PEDIATRICS
by: A.Yu. Shcherbina, et al.
Published: (2010-01-01)

Intravenous immunoglobulin in dermatology
by: Dhar Sandipan
Published: (2009-01-01)